Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Expects Lexapro To Lead Market By ’05; Will Re-Launch In GAD In ’04

Executive Summary

Forest expects its anti-depressant Lexapro (escitalopram) to lead the selective serotonin reuptake inhibitor market by 2005

You may also be interested in...



Forest Lexapro “Re-Launch” For Generalized Anxiety Set For Mid-January

Forest will begin promotion of Lexapro for generalized anxiety disorder in mid-January

Forest Lexapro “Re-Launch” For Generalized Anxiety Set For Mid-January

Forest will begin promotion of Lexapro for generalized anxiety disorder in mid-January

Forest Lexapro Strategy Changes: Reps Encouraging Switches From Celexa

Forest is restructuring its sales representative compensation program to encourage switches from the company's antidepressant Celexa to the follow-on selective serotonin reuptake inhibitor Lexapro

Related Content

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel